Paris-based Inato, a platform that makes clinical trials more accessible, announced that it has raised $20M in a Series A2 round of funding.
The capital comes from Cathay Innovation, Obvious Ventures, and new investors La Maison and Top Harvest Capital.
Inato says the new funding will fuel its continued product innovation, international growth, and hiring of top talent.
The French company will also advance its diverse product offering to enable sponsors to meet their diversity goals based on new FDA requirements.
The company will also invest in oncology-specific innovation to increase access to care.
Inato will also further define and scale its data model to continue to improve matching reliability between community sites and sponsor trials.
Founded in 2020, Inato makes clinical trials more accessible, inclusive, and efficient for patients, community-based clinical researchers, and pharmaceutical companies globally.
The company’s platform connects global pharmaceutical companies with a more extensive network of community research sites, facilitating the matching of the right trial to the right patient.
Since its inception, the Inato platform has quickly become a trusted two-sided platform with over 2,500 community research sites that support more than 70 disease areas in more than 60 countries.
To date, the company has formed partnerships with a third of the top 30 pharmaceutical companies to make their medical research more accessible, inclusive, and efficient.
Read more on Tech Gist Africa:
Paris-based Carbon Maps bags €4M
Paris-based Ever Dye raises €3.4M
Shark Robotics, whose robot famously battled the Notre Dame de Paris cathedral fire; raises €10M
